89bio reports Q1 EPS (49c), consensus (57c)

As of March 31, 2025, 89bio (ETNB) had cash, cash equivalents and marketable securities of approximately $638.8M. “We have entered 2025 with strong momentum, fueled by continued progress in our two global Phase 3 trials in advanced MASH. Both trials are actively screening and enrolling patients across more than 20 countries, with most sites now activated and strong investigator enthusiasm driving enrollment,” said Rohan Palekar, Chief Executive Officer of 89bio. “A recently published meta-analysis in Hepatology1 ranked pegozafermin among the most effective agents for achieving fibrosis improvement and MASH resolution-reinforcing its differentiated profile and the growing recognition of its potential. With best-in-class relative risk reduction, a favorable safety and tolerability profile, and convenient dosing, we believe pegozafermin is well positioned as a leading candidate to treat this large and underserved patient population.” “Looking ahead, we continue to expect topline results from our Phase 3 ENTRUST trial in SHTG in first quarter of 2026, followed by data readouts from ENLIGHTEN-Fibrosis in the first half of 2027 and ENLIGHTEN-Cirrhosis in 2028-the latter two of which are intended to support the accelerated approval of pegozafermin to treat patients with F2-F3 and compensated F4 MASH,” added Mr. Palekar. “To support our development and commercial readiness efforts, we have implemented a flexible, global manufacturing strategy with optionality for our manufacturing footprint across geographies, including the United States for the drug product.”